Synapse Open Synapse
Biology

Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

BioPharma Dive · · 2 min read

The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.

Latest from BioPharma Dive